An explanation of the clinical phenotypes of myelofibrosis.
Videos
Dr Raajit Rampal assesses whether frontline treatment with ruxolitinib was appropriate in the presented patient case with supporting data from the COMFORT-I and -II clinical trials.
Raajit Rampal, MD, PhD, reviews the case of a 67-year-old man with primary myelofibrosis and shares his initial impressions.
Amaia Lujambio Goizueta, PhD, discusses a new approach to overcoming resistance to immunotherapy for patients with hepatocellular carcinoma.
Farrukh Awan, MD, discusses the results of the phase 3 ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.
Roger Li, MD, shares the results of the phase 2 CORE1 clinical trial, which evaluated CG0070 in combination with pembrolizumab for the treatment of patients with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
Ronald L. Paquette, MD, discusses the choice of using bone marrow and stem cell transplants as treatment for patients with myelodysplastic syndrome.
Neal Shore, MD, FACS discusses results from a post-hoc analysis of the phase 3 ARCHES trial.
Study results may indicate for a potential alternative treatment option to address the unmet needs for elderly patients with newly diagnosed mantle cell lymphoma, according to Michael Wang, MD.
Lori Wirth, MD, discusses her experience with NTRK-targeted therapies for patients with thyroid cancer.
Ravi Salgia, MD, PhD, discusses the ways in which oncologists can watch out for non-small cell lung cancer that transforms to small-cell lung cancer.
Description: Before closing out his discussion on polycythemia vera management, Prithviraj Bose, MD, shares excitement for emerging therapeutics in this setting.
Expert perspectives on long-term management of patients with polycythemia vera, with regard for the risk of developing secondary MF or AML.
In discussing the role of ruxolitinib in HU-resistant or intolerant PV, expert Prithviraj Bose, MD, highlights data from the RESPONSE and RESPONSE-2 clinical trials.
Considerations for therapy when patients with polycythemia vera experience hydroxyurea resistance or intolerance.
A comprehensive review of the treatment armamentarium for polycythemia vera, as well as strategies to monitor patients on therapy in this setting.
Expert Prithviraj Bose, MD, reviews standard practices in diagnosing and risk stratifying uncontrolled polycythemia vera in the context of a patient case.
Andreas Saltos, MD, discusses a phase 1 trial of binimetinib and erlotinib for patients with non–small cell lung cancer and EGFR or KRAS mutations.
EP. 6B: Clinical Experience With Trilaciclib in Patients With Extensive-Stage Small Cell Lung Cancer
In this companion article, Dr. Jyoti Malhotra discusses her clinical experience using trilaciclib for the management of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer.
Steven M. Albelda, MD, discusses the limited successes of CAR T cells in solid tumors.
Shawn Dason, MD, a urologic oncologist at The Ohio State University Comprehensive Cancer Center, discusses the decline of prostate cancer screening in recent years and how it has impacted care of patients with prostate cancer overall.
David Barrington, MD, discusses adjuvant treatments that are currently available for patients with stage 1B, grade 3 endometrial cancer.
Nazli Dizman, MD, discusses what community oncologists should keep in mind about gut microbiome when treating their patients.
John L. Marshall, MD, discusses of the adverse event profile of fam-trastuzumab deruxtecan-nxki in patients with locally advanced or metastatic HER2-positive gastric cancer.
Mazyar Shadman, MD, MPH, discusses the use of MB-106 for the treatment of patients with relapsed or refractory B-cell nonHodgkin lymphoma and chronic lymphocytic leukemia.
Before closing out his discussion on newly diagnosed multiple myeloma, Ajay K. Nooka, MD, MPH, FACP, emphasizes the continued role of transplantation in this setting.
Ajay K. Nooka, MD, MPH, FACP, shares insight on strategies to optimally deliver maintenance therapy and manage toxicities in patients with multiple myeloma.
Considerations for assessing treatment response and electing to continue therapy in patients with newly diagnosed multiple myeloma.
Insight on the role of isatuximab and VRd in patients with newly diagnosed multiple myeloma following data from the GMMG-HD7 study.
Shifting his focus to the MASTER study in newly diagnosed multiple myeloma, Ajay K. Nooka, MD, MPH, FACP, highlights the role of daratumumab with KRd.